This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Technology / Pasithea PAS-004 gets FDA Orphan Drug
Tech Orphan Drug Designation

Pasithea PAS-004 gets FDA Orphan Drug

Analysis based on 9 articles · First reported Jun 02, 2026 · Last updated Jun 02, 2026

Sentiment
60
Attention
4
Articles
9
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The Orphan Drug Designation for PAS-004 is expected to positively impact Pasithea Therapeutics' stock due to potential tax credits, fee exemptions, and market exclusivity. This development could accelerate the drug's path to market, addressing a significant unmet medical need for ALS patients.

Biotechnology Pharmaceuticals
Event Summary

Pasithea Therapeutics Corp. announced that the United States — Food and Drug Administration (FDA) granted Orphan Drug Designation to its lead drug candidate, PAS-004, for the treatment of ALS (ALS). This designation is given to therapies for rare diseases affecting fewer than 200,000 people in the United States and provides benefits such as tax credits for clinical trials, exemption from certain FDA fees, and potential for seven years of market exclusivity. Dr. Tiago Reis Marques, CEO of Pasithea Therapeutics, highlighted the critical need for new ALS treatments. In November 2025, the ALS Association also awarded Pasithea Therapeutics a $1 million grant to study PAS-004 for ALS.

Entities Involved
stock
Pasithea Therapeutics
Pasithea Therapeutics received Orphan Drug Designation for its drug candidate PAS-004, which could provide significant benefits like tax credits, fee exemptions, and market exclusivity, positively impacting its stock and development efforts.
Importance 100.0 Sentiment 70.0
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration granted Orphan Drug Designation to PAS-004, facilitating its development for a rare disease.
Importance 90.0 Sentiment 0.0
per
Tiago Reis Marques
Tiago Reis Marques, CEO of Pasithea Therapeutics, commented on the significance of the Orphan Drug Designation for PAS-004 in addressing the unmet medical need for ALS.
Importance 60.0 Sentiment 0.0
ngo
ALS Association
The ALS Association awarded a $1 million grant to Pasithea Therapeutics to study PAS-004 for ALS, demonstrating support for its development.
Importance 50.0 Sentiment 0.0
cnt
United States
The United States is the country where the United States — Food and Drug Administration operates and where the Orphan Drug Designation applies, affecting diseases with fewer than 200,000 people.
Importance 30.0 Sentiment 0.0
Relationships
United States — Food and Drug Administration related ↔ United States
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.